Mystic Asset Management’s AbbVie ABBV Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$5.1M Sell
20,254
-61
-0.3% -$13.1K 1.09% 21
2026
Q1
$4.42M Sell
20,315
-224
-1% -$49.7K 1.02% 25
2025
Q4
$4.69M Sell
20,539
-394
-2% -$89.8K 1.06% 22
2025
Q3
$4.85M Buy
20,933
+54
+0.3% +$11K 1.09% 21
2025
Q2
$3.88M Buy
20,879
+26
+0.1% +$4.83K 0.94% 26
2025
Q1
$4.37M Sell
20,853
-470
-2% -$91.4K 1.15% 22
2024
Q4
$3.79M Buy
21,323
+5,770
+37% +$1.06M 1.02% 26
2024
Q3
$3.07M Sell
15,553
-204
-1% -$38.1K 1.16% 20
2024
Q2
$2.7M Buy
15,757
+109
+0.7% +$18.1K 1.09% 24
2024
Q1
$2.85M Buy
15,648
+551
+4% +$95K 1.18% 24
2023
Q4
$2.34M Sell
15,097
-719
-5% -$105K 1.12% 24
2023
Q3
$2.36M Buy
15,816
+75
+0.5% +$11K 1.32% 23
2023
Q2
$2.12M Sell
15,741
-399
-2% -$58.5K 1.14% 26
2023
Q1
$2.57M Sell
16,140
-20
-0.1% -$3.06K 1.42% 17
2022
Q4
$2.61M Buy
16,160
+25
+0.2% +$3.83K 1.48% 16
2022
Q3
$2.17M Buy
16,135
+100
+0.6% +$14.3K 1.39% 17
2022
Q2
$2.46M Buy
16,035
+715
+5% +$109K 1.5% 14
2022
Q1
$2.48M Sell
15,320
-500
-3% -$72.6K 1.34% 18
2021
Q4
$2.14M Buy
+15,820
New +$1.87M 1.01% 24

Other funds holding ABBV

Mystic Asset Management's ABBV Position: Q2 2026 in Review

Mystic Asset Management reduced its AbbVie (ABBV) stake by 0.3% in Q2 2026, selling an estimated $13.1K and leaving 20,254 shares worth $5.1M. The position accounts for 1.09% of the portfolio, ranked #21.

Mystic Asset Management first reported a position in ABBV in Q4 2021 and has held it in 19 quarters since. 4,193 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

  • Mystic Asset Management held 20,254 shares of AbbVie worth $5.1M as of Q2 2026.
  • Mystic Asset Management sold 61 AbbVie shares in Q2 2026, an estimated $13.1K.
  • AbbVie made up 1.09% of Mystic Asset Management's portfolio in Q2 2026, its #21 holding.
  • Mystic Asset Management first reported a position in AbbVie in Q4 2021 and has held it in 19 quarters since.
  • 4,193 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Mystic Asset Management's 13F filing for Q2 2026, filed 11 Aug 2026.